患有卵巢癌的脆弱老年患者——是时候停止治疗不足了。 - Suppr

Suppr

超能文献

Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating.

作者信息

Wethington Stephanie L, Armstrong Deborah K, Gaillard Stéphanie L

机构信息

Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.

出版信息

JAMA Oncol. 2021 Jun 1;7(6):831-833. doi: 10.1001/jamaoncol.2021.0468.

DOI:10.1001/jamaoncol.2021.0468

PMID:33885717

Abstract

摘要

相似文献

Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating.

JAMA Oncol. 2021 Jun 1;7(6):831-833. doi: 10.1001/jamaoncol.2021.0468.

What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?-Reply.

JAMA Oncol. 2021 Nov 1;7(11):1727. doi: 10.1001/jamaoncol.2021.4131.

Epithelial ovarian cancer in older women: defining the best management approach.

Am Soc Clin Oncol Educ Book. 2015:e311-21. doi: 10.14694/EdBook_AM.2015.35.e311.

What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?

JAMA Oncol. 2021 Nov 1;7(11):1725-1726. doi: 10.1001/jamaoncol.2021.4125.

What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?

JAMA Oncol. 2021 Nov 1;7(11):1726-1727. doi: 10.1001/jamaoncol.2021.4128.

[Epithelial ovarian cancer and elderly patients. Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

Gynecol Obstet Fertil Senol. 2019 Feb;47(2):238-249. doi: 10.1016/j.gofs.2018.12.008. Epub 2019 Feb 1.

Treatment of ovarian cancer in the older woman.

Gynecol Oncol. 2015 Jan;136(1):136-42. doi: 10.1016/j.ygyno.2014.10.028. Epub 2014 Nov 3.

Planning treatment for women with recurrent epithelial ovarian cancer.

Oncology (Williston Park). 2013 Apr;27(4):304, 306.

[Several thoughts about chemotherapy of ovarian carcinoma].

Zhonghua Fu Chan Ke Za Zhi. 2011 Dec;46(12):898-900.

The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.

Clin Oncol (R Coll Radiol). 2013 Jan;25(1):75. doi: 10.1016/j.clon.2012.09.007. Epub 2012 Nov 10.

引用本文的文献

Development and validation of a nomogram for predicting overall and cancer-specific survival in elderly patients (≥ 65 years) with epithelial ovarian cancer.

Eur J Med Res. 2025 Sep 1;30(1):831. doi: 10.1186/s40001-025-03114-0.

The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States: a retrospective cohort study based on the SEER database.

Discov Oncol. 2025 Apr 17;16(1):545. doi: 10.1007/s12672-025-02205-y.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.

J Clin Oncol. 2025 Mar;43(7):868-891. doi: 10.1200/JCO-24-02589. Epub 2025 Jan 22.

Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen.

Front Oncol. 2023 Dec 13;13:1289379. doi: 10.3389/fonc.2023.1289379. eCollection 2023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating.

作者信息

Wethington Stephanie L, Armstrong Deborah K, Gaillard Stéphanie L

机构信息

Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.

出版信息

JAMA Oncol. 2021 Jun 1;7(6):831-833. doi: 10.1001/jamaoncol.2021.0468.

DOI:10.1001/jamaoncol.2021.0468

PMID:33885717

Abstract

摘要

相似文献

Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating.

JAMA Oncol. 2021 Jun 1;7(6):831-833. doi: 10.1001/jamaoncol.2021.0468.

What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?-Reply.

JAMA Oncol. 2021 Nov 1;7(11):1727. doi: 10.1001/jamaoncol.2021.4131.

Epithelial ovarian cancer in older women: defining the best management approach.

Am Soc Clin Oncol Educ Book. 2015:e311-21. doi: 10.14694/EdBook_AM.2015.35.e311.

What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?

JAMA Oncol. 2021 Nov 1;7(11):1725-1726. doi: 10.1001/jamaoncol.2021.4125.

What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?

JAMA Oncol. 2021 Nov 1;7(11):1726-1727. doi: 10.1001/jamaoncol.2021.4128.

Gynecol Obstet Fertil Senol. 2019 Feb;47(2):238-249. doi: 10.1016/j.gofs.2018.12.008. Epub 2019 Feb 1.

Treatment of ovarian cancer in the older woman.

Gynecol Oncol. 2015 Jan;136(1):136-42. doi: 10.1016/j.ygyno.2014.10.028. Epub 2014 Nov 3.

Planning treatment for women with recurrent epithelial ovarian cancer.

Oncology (Williston Park). 2013 Apr;27(4):304, 306.

[Several thoughts about chemotherapy of ovarian carcinoma].

Zhonghua Fu Chan Ke Za Zhi. 2011 Dec;46(12):898-900.

The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.

Clin Oncol (R Coll Radiol). 2013 Jan;25(1):75. doi: 10.1016/j.clon.2012.09.007. Epub 2012 Nov 10.

引用本文的文献

Development and validation of a nomogram for predicting overall and cancer-specific survival in elderly patients (≥ 65 years) with epithelial ovarian cancer.

Eur J Med Res. 2025 Sep 1;30(1):831. doi: 10.1186/s40001-025-03114-0.

The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States: a retrospective cohort study based on the SEER database.

Discov Oncol. 2025 Apr 17;16(1):545. doi: 10.1007/s12672-025-02205-y.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.

J Clin Oncol. 2025 Mar;43(7):868-891. doi: 10.1200/JCO-24-02589. Epub 2025 Jan 22.

Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen.

Front Oncol. 2023 Dec 13;13:1289379. doi: 10.3389/fonc.2023.1289379. eCollection 2023.